TITLE

Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: a single centre randomised, double blind, placebo controlled, crossover study

AUTHOR(S)
Ulrik, C S
PUB. DATE
July 1995
SOURCE
Thorax;Jul1995, Vol. 50 Issue 7, p750
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
66075354

 

Related Articles

  • Inhaled Salmeterol: A Review of its Efficacy in Chronic Obstructive Pulmonary Disease. Jarvis, B.; Markham, A. // Drugs & Aging;2001, Vol. 18 Issue 6, p441 

    Inhaled salmeterol is a long-acting, selective β-adrenoceptor agonist bronchodilator. The drug has been compared with placebo, ipratropium bromide and oral theophylline in patients with chronic obstructive pulmonary disease (COPD) in randomised, clinical trials. Inhaled salmeterol 50µg...

  • Onset of Action of Formoterol versus Salmeterol via Dry Powder Inhalers in Moderate Chronic Obstructive Pulmonary Disease. Cazzola, Mario; Paggiaro, Pierluigi; Palange, Paolo; Bjermer, Leif; Ausin, Pilar; Carlsson, Lars-Goran; Ekelund, Jan; Lotvall, Jan // Clinical Drug Investigation;2012, Vol. 32 Issue 3, p147 

    Background: Bronchodilator therapy is central to the symptomatic management of chronic obstructive pulmonary disease (COPD), and treatment with short-acting bronchodilators is recommended in patients with mild COPD. Objective: This study aimed to evaluate the onset of effect of single-dose...

  • Salmeterol/Fluticasone Propionate: A Review of its Use in the Treatment of Chronic Obstructive Pulmonary Disease. Keating, Gillian M.; McCormack, Paul L. // Drugs;2007, Vol. 67 Issue 16, p2383 

    Salmeterol/fluticasone propionate (Seretide®, Advair®, Viani®) administered using a multidose dry powder inhaler (Diskus®, Accuhaler®) is approved for use in the treatment of chronic obstructive pulmonary disease (COPD) in numerous countries. Salmeterol/fluticasone propionate...

  • Uplifting times for COPD. Halpin, David M.G. // Primary Care Respiratory Journal;Dec2008, Vol. 17 Issue 4, p197 

    The article focuses on the randomised double-blind placebo-controlled study which examined the effects of tiotropium on chronic obstructive pulmonary disease (COPD) patients. Researchers allowed patients to take other respiratory medications including long-acting beta-agonists (LABA) and inhaled...

  • Efficacy of Inhaled Fluticasone Plus Salmeterol in COPD. Miller, Karl E. // American Family Physician;5/1/2004, Vol. 69 Issue 9, p2239 

    Deals with the findings of a study on the efficacy of fluticasone propionate and salmeterol in patients with chronic obstructive pulmonary disease (COPD). Use of bronchodilators as first-line therapy treatment for COPD; Effect of inhaled corticosteroids in patients with COPD; Effectiveness of...

  • Which Inhaler Combination is Best for COPD Treatment? Elliott, William T. // Clinical Cardiology Alert;Apr2007 Pharmacology Watch, p1 

    The article focuses on two studies that have looked at the effects of various inhaler combinations on outcomes in patients with chronic obstructive pulmonary disease (COPD). The first study from British researchers compared the use of salmeterol plus fluticasone inhaler twice daily with...

  • Steroid Response in Stable Chronic Obstructive Pulmonary Disease. Mendella, L. A.; Manfreda, J.; Warren, C. P. W.; Anthonisen, N. R. // Annals of Internal Medicine;Jan82, Vol. 96 Issue 1, p17 

    Compares a two-week course of methylprednisolone with placebo in a double-blind crossover trial in patients with stable chronic obstructive pulmonary disease. Baseline lung function in patients with chronic obstructive pulmonary disease; Criteria for differentiating patients who respond to...

  • Cardiovascular events in patients with COPD: TORCH Study results. Calverley, Peter M. A.; Anderson, Julie A.; Celli, Bartolome; Ferguson, Gary T.; Jenkins, Christine; Jones, Paul W.; Crim, Courtney; Willits, Lisa R.; Yates, Julie C.; Vestbo, Jørgen // Thorax;Aug2010, Vol. 65 Issue 8, p8 

    Background Previous studies have suggested that long-term use of β agonists to treat chronic obstructive pulmonary disease (COPD) may increase the risk of cardiovascular adverse events. In this post hoc analysis, data from the TOwards a Revolution in COPD Health (TORCH) study were used to...

  • Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease. Calverley, Peter M.A.; Anderson, Julie A.; Celli, Bartolome; Ferguson, Gary T.; Jenkins, Christine; Jones, Paul W.; Yates, Julie C.; Vestbo, Jørgen // New England Journal of Medicine;2/22/2007, Vol. 356 Issue 8, p775 

    Background: Long-acting beta-agonists and inhaled corticosteroids are used to treat chronic obstructive pulmonary disease (COPD), but their effect on survival is unknown. Methods: We conducted a randomized, double-blind trial comparing salmeterol at a dose of 50 μg plus fluticasone propionate...

  • Clinical trial design in chronic obstructive pulmonary disease: current perspectives and considerations with regard to blinding of tiotropium. Kai-Michael Beeh; Beier, Jutta; Donohue, James F. // Respiratory Research;Jun2012, Vol. 13 Issue 6, p1 

    Randomised, double-blind, controlled trials are considered the gold standard for evaluating a pharmacological agent, as they minimise any potential bias. However, it is not always possible to perform double-blind trials, particularly for medications delivered via specific devices, e.g. inhalers....

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics